AQ 280
Alternative Names: AQ-280; LEO-142397; RegulusLatest Information Update: 28 May 2025
At a glance
- Originator LEO Pharma
- Developer Aqilion
- Class Anti-inflammatories; Small molecules
- Mechanism of Action Janus kinase 1 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Phase I Eosinophilic oesophagitis
Most Recent Events
- 16 May 2025 Aqilion announces intention to submit IND for phase II trial in Eosinophilic oesophagitis US, Canada and Europe
- 16 May 2025 US FDA approves IND application for AQ 280 in Eosinophilic oesophagitis
- 12 May 2025 Aqilion plans a clinical trial for Eosinophilic oesophagitis (In volunteers) in USA (PO, Tablet) in June 2025